US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.71 against a street estimate of -0.35 — a miss of 102.9%.
Analysts rate Organogenesis Holdings Inc a hold (0 buy, 2 hold, 0 sell out of 2) with an average price target of $2.00.
| Fund | Stake |
|---|---|
| Morgan Stanley - Brokerage Accounts | 9.11% |
| Soleus Capital Management, L.P. | 7.88% |
| BlackRock Inc | 5.63% |
| Assenagon Asset Management SA | 3.06% |
| Dimensional Fund Advisors, Inc. | 2.37% |
| AQR Capital Management LLC | 2.34% |
| Vanguard Capital Management, LLC | 2.26% |
| D. E. Shaw & Co LP | 2.24% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Organogenesis Holdings Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.